# China NMPA Drug Inspection - Guangxi Yulin Fantawild Pharmaceutical Co., Ltd. - Heat-clearing and detoxifying tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guangxi-yulin-fantawild-pharmaceutical-co-ltd/f1d13498-9579-4bb7-b6ff-9bf7914b1207/
Source feed: China

> China NMPA drug inspection for Guangxi Yulin Fantawild Pharmaceutical Co., Ltd. published January 26, 2017. Drug: Heat-clearing and detoxifying tablets. On January 26, 2017, China's State Administration for Market Regulation (formerly SFDA) announced findings of 14 batches

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 17 of 2017 from the State Administration for Market Regulation regarding 14 batches of substandard drugs.
- Company Name: Guangxi Yulin Fantawild Pharmaceutical Co., Ltd.
- Publication Date: 2017-01-26
- Drug Name: Heat-clearing and detoxifying tablets
- Inspection Finding: The non-compliant items included content determination, as well as ammonia, related substances, total aerobic bacteria count, fill weight variation, moisture content, disintegration time, and weight variation under the inspection items.
- Action Taken: The relevant provincial (autonomous region, municipality) food and drug administrations have taken control measures such as sealing and seizing, requiring enterprises to suspend sales and use, and recall products; the State Food and Drug Administration has required the provincial (autonomous region, municipality) food and drug administrations where the production enterprises are located to investigate the enterprises, handle them in accordance with the law, and order the production enterprises to thoroughly investigate the causes, make thorough rectifications, and promptly disclose the relevant information to the public.
- Summary: On January 26, 2017, China's State Administration for Market Regulation (formerly SFDA) announced findings of 14 batches of substandard drugs from ten pharmaceutical companies, following tests by six drug testing institutions. Companies implicated included Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd., Guangxi Yulin Fangte Pharmaceutical Co., Ltd., Henan Wandong Pharmaceutical Co., Ltd., Shanghai Xinyi Pharmaceutical Co., Ltd., Hengtuo Group Rensheng Pharmaceutical Co., Ltd., and others. The substandard products ranged from Alanylglutamine injection to various tablets, capsules, and syrups. The main quality control issues involved failures in content determination, tests for ammonia, related substances, total aerobic bacteria count, fill weight variation, moisture content, disintegration time, and weight variation. Provincial food and drug administrations were immediately instructed to implement control measures, including sealing and seizing the affected drugs, suspending sales and usage, and initiating recalls. Operating under the 'Drug Administration Law of the People's Republic of China' and relevant regulations, manufacturers are required to thoroughly investigate the causes, implement comprehensive rectifications, and promptly disclose information. Authorities are also tasked with investigating these companies and handling cases according to law.

Company: https://www.globalkeysolutions.net/companies/guangxi-yulin-fantawild-pharmaceutical-co-ltd/86ab6654-2079-42ee-b87f-8b8ed3178aa5/